Drug Trial Radar · NCT03975374
To Study Efficacy and Safety of Tobradex Eye Drop Suspension vs Tobramycin/Dexamethasone Ophthalmic Suspension
Last checked: Nov 19, 2026Latest source record: Jun 5, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
5,000
Planned (sponsor's estimate)
Start
Jun 15, 2019
Primary completion
Jul 1, 2019
Study completion Jun 30, 2020
Sponsor
- Lead sponsor
- Sutphin DrugsIndustry
- Sponsor type
- Industry
- First posted
- Jun 5, 2019
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of the study is to compare and describe efficacy and safety of Tobradex ophthalmic suspension versus generic Tobramycin/dexamethasone Suspension in treatment of Blepharoconjuctivitis through clinical parameters
Conditions
- Blepharo Conjunctivitis
Interventions
Tobramycin/dexamethasone opthalmic solutionDrug
To compare efficacy and safety in randomized patients recieving Tobradex versus Tobramycin/Dexamethasone opthamic Solution
Tobradex Opthalmic SolutionDrug
Tobradex Opthalmic Solution
Primary outcomes
What the sponsor says the trial is designed to measure.
- Sign and symptoms composite scoreTime frame: 10 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sutphin Drugs
Jamaica, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.